eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
Healthcare
$5.54 +16.75%
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
52W Low $6.33High $18.40
Volume 0.01M
Average 0.01M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$9.72M
FY 2025 · Annual
Net Income
-$9.16M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 59.41K | 147.75K | 0 | 267.38K | 0 |
| Gross Profit | (59.41K) | (147.75K) | 0 | (267.38K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 454.45K | 348.08K | 527.48K | 1.87M | 3.71M |
| Selling, General & Admin | 778.99K | 836.83K | 1.34M | 3.8M | 5.91M |
| Operating Expenses | 1.23M | 1.18M | 1.8M | 5.66M | 9.72M |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | 287.96K |
| EBITDA | (1.15M) | (1.18M) | (1.8M) | (5.59M) | (8.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.29M) | (1.33M) | (1.8M) | (5.93M) | (9.72M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 98 | 100 | 77.61K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 83.74K | 98 | (199.9K) | 70.77K | 452.53K |
| Income Before Tax | (1.21M) | (1.33M) | (2M) | (5.86M) | (9.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 63.56K | 42.27K | 0 | (105.21K) |
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| EPS (Diluted) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| 8.13M | 8.13M | 8.13M | 8.13M | 8.38M | |
| 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
EXOZ Earnings Waterfall · TTM
NASDAQ:EXOZ · Revenue to Net Income
Key Ratios
EPS$-1.15
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-9.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$9.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.15, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 |
How much revenue does EXOZ generate?
eXoZymes, Inc. (EXOZ) reported $0.00 of revenue in fiscal 2025.
Is EXOZ profitable?
eXoZymes, Inc. (EXOZ) reported -$9.16M of net income.
Continue the stock analysis
Jump to another research area for this company.